OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD

Thats the thing, I dont think Toffee stated 'short term impact' - that I'd agree with.

As you point out alexchry, its worth considering the wider, less apparent and longer term implications.
With ten Lenti licences signed, if just one of those yields a product that makes it to market, on average, the risk adjusted NPV of royalties from that would be in the region of £20m IMO.

Since
a)each party will likely discover more than one pre-clinical candidate
b)OXB has to date demonstrated a high efficiency in yielding pre-clinical products with impressive results
My money is on more than just one external Lenti product getting to market.